Saturday, 3 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

Ridgepost Capital Reports Fourth Quarter and Full Year 2025 Earnings Results

View original at globenewswire.com
Ridgepost Capital Reports Fourth Quarter and Full Year 2025 Earnings Results Record Full Year Fundraising and Deployment of $5.1 Billion Fee-Paying AUM increased 15% year over year DALLAS, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Non-GAAP financial measures including FRR, FRE, ANI, and Fully Diluted ANI per share provide better comparability of ongoing operating performance to prior periods.

    80% confidence
  • The 2025 earnings report marks Ridgepost Capital's first under its new identity, representing platform expansion and strategy integration work done over the past few years.

    80% confidence
  • During 2025, Ridgepost Capital raised and deployed a record $5.1 billion in organic gross new fee-paying assets and exceeded initial annual organic fundraising guidance by over $1 billion.

    80% confidence
  • The Dubai office opening and CAIS collaboration will meaningfully increase Ridgepost Capital's global footprint and enable capturing of growing demand for alternatives in the wealth ecosystem.

    80% confidence
  • Total assets under management exceeded $43 billion as of December 31, 2025.

    80% confidence
  • Fee-Paying Assets Under Management increased 15% year over year to $29.4 billion as of December 31, 2025.

    80% confidence
  • The acquisition of Stellus Capital Management advances Ridgepost Capital's long-term strategy of partnering with best-in-class investment managers by adding a leading direct lending franchise.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com